Zynex Business Model Canvas

Trusted suppliers ensure quality electrodes, batteries, leads and electronics, supporting Zynex's medical device portfolio and reported 2024 revenue of $177.5 million. Dual-sourcing and quarterly QA audits protect supply continuity and regulatory compliance. Cost, reliability and FDA/ISO alignment drive supplier selection. Co-development agreements with manufacturers target improved durability and patient comfort.

Clinical prescribers drive adoption (50M US adults with chronic pain, CDC 2019); Zynex 2024 revenue $177.5M supports prescriber education and refill programs. Payers/Medicare (65M beneficiaries in 2024) and PBMs (~250M lives) secure reimbursement; GPOs reach >90% hospitals and 6,000+ ASCs enable procurement scale. Suppliers, KOLs and academic studies sustain quality, coverage and evidence.

Maintain FDA clearances and EU MDR 2017/745–aligned labeling with active post-market surveillance per ISO 13485:2016 and 21 CFR Part 820, plus complaint handling and audit-ready reporting. Manage audits, CAPAs, and vigilance procedures under IEC 62304 and ISO 14971 risk management. Ensure cybersecurity and electrical safety via IEC 60601 series and IEC 62304 controls. Global registrations (EU, Canada, others) enable international expansion.

Design, prototyping, waveform optimization and clinical validation drive differentiation and adherence; algorithm tuning targets clinical effect and comfort. QMS and manufacturing ensure ISO 13485 and 21 CFR Part 820 alignment (2024) with CAPA, lot traceability and supplier control. Market access secures Medicare/commercial coverage while sales, clinic training and remote patient onboarding sustain referrals and reuse.

FDA 510(k) clearances and ISO 13485 certification enable Zynex market access and reimbursement pathways, with 510(k) reviews typically completed in about 3–6 months. A robust QMS supports successful audits and tender eligibility, shortening procurement cycles. Well-maintained documentation accelerates subsequent submissions and supplements, while compliance strengthens trust with clinicians and payers.

Zynex key resources combine a 2024 IP portfolio (patents, waveform libraries) and manufacturing capacity enabling >50k units/year. Regulatory certifications (FDA 510(k), ISO 13485) and QMS shorten approvals. Field sales, clinical educators, and reimbursement teams drive adoption and recurring revenue; >40 peer-reviewed studies by 2024 support uptake.

Covered as durable medical equipment by CMS when medically necessary and reimbursed by many commercial payers, Zynex therapies tap established reimbursement pathways. By addressing pain and mobility early they can reduce downstream costs tied to complications and readmissions within the $4.5 trillion US health system (2023 CMS). Predictable recurring supply costs aid provider budgeting. Strong clinical documentation supports payer approvals.

Zynex provides FDA-cleared, non-invasive neuromodulation and electrotherapy that reduces opioid use and supports hospital stewardship amid >107,000 US drug overdose deaths (2022; ~80,000 opioid-involved). Ergonomic, portable devices boost home adherence (+22% pilot 2024) and deliver PRO gains (+18 PROM pts pilot 2024), tapping a $1.4B wearable pain market (2024) with DME reimbursement pathways.

Assign dedicated reps to key clinics and the roughly 6,100 US hospitals (2024) to coordinate training, in‑facility sampling and controlled trials, driving faster adoption timelines. Reps proactively manage formulary and clinical pathway inclusion to improve utilization and reimbursement. Each account has a single point of contact to resolve escalations, reducing response time and protecting revenue streams.

Prescriber education, concierge in‑home setup, dedicated reps for ~6,100 US hospitals (2024), and structured prior‑auth/appeals build high-touch, revenue-protecting relationships. SMS/email nudges, support lines and connected-program reporting boost adherence up to 20% and pain 1–3 NPRS points, aiding adoption and reimbursement.

Patient reorder portals and call centers streamline supply replenishment through integrated digital and phone workflows, shortening order cycles and reducing manual errors. Automated reminders and refill prompts increase patient compliance and device utilization. Embedded secure payments and real-time insurance verification reduce administrative friction and claim denials. These channels collectively boost patient retention and lifetime value.

Field reps, clinical specialists and local sales accelerate hospital adoption via demos, pilots and contracting, shortening procurement by ~30% and leveraging Nasdaq listing for credibility. DME/distributor partnerships expand reach into rural/metropolitan markets with lower fixed costs. Patient portals, call centers and auto-refills boost retention and LTV. Conferences, KOLs and GPO placement (≈70% hospital coverage) drive scalable leads and group pricing (10–20%).

Hospitals and ASCs (≈6,090 hospitals and ≈5,800 ASCs in the US per AHA/ASCA 2023) are institutional buyers for perioperative and rehab pathways, prioritizing outcomes, cost reduction and opioid stewardship. They require solutions that integrate with discharge workflows and remote monitoring to lower LOS and readmissions under CMS value-based programs. They prefer contracted vendors with documented ROI and compliance.

End-users (≈50M US adults with chronic pain) seek at-home, easy-to-use neuromodulation with recurring consumables; prescribers (≈1.1M US physicians in 2024) require strong evidence and workflow fit; hospitals/ASCs (≈6,100 hospitals, ≈5,800 ASCs) prioritize outcomes and ROI; payers (Medicare ≈64M enrollees in 2024) demand total-cost evidence for coverage.

Sales, marketing, and training for Zynex center on field force compensation, travel, and in-home demos, aligning with medtech peers that spent roughly 20–30% of revenue on SG&A in 2024; conference and educational content accounted for a material share of that spend. Digital marketing and patient materials plus sample and starter kit programs drive adoption and add recurring unit costs per new patient.

Unit COGS driven by components, assembly and test (assembly labor 20–30% of device cost); recurring disposables ~10–15% lifetime revenue per patient; SG&A ~20–30% revenue (2024); R&D: device engineer pay ~$130k, prototypes $50k–250k, pivotal trials $0.5–5M; 510(k) fee ≈ $20,870; avg breach cost $4.45M (2024).

Extended service plans and repairs generate predictable, relationship-deepening income for Zynex, with service and rental contracts supporting after-sales revenue alongside device sales; in 2024 Zynex reported total revenue of $98.8 million, underscoring the contribution of recurring streams. Calibration and replacements, delivered through scheduled maintenance, reduce downtime and protect clinical outcomes. SLA-backed support for institutions secures higher retention and upsell potential, improving lifetime customer value.

Revenue streams: one-time device sales, recurring consumables, service/maintenance and rentals/trial-to-own, with Medicare/Commercial reimbursement support under DME/Part B; 2024 total revenue was $98.8 million. Consumables and auto-ship programs drive repeat purchases and improve retention. Rentals and trial-to-own smooth recognition and convert to purchases when outcomes justify coverage.